跳至主要内容
临床试验/NCT02010047
NCT02010047已完成不适用

A Study to Compare the Performance of a qPCR-based Assay to Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) in the Detection of Anaplastic Lymphoma Kinase (ALK) Fusion Mutations in Formalin Fixed Paraffin-embedded (FFPE) Tissue From Non-small Cell Lung Cancer (NSCLC) Patients.

British Columbia Cancer Agency14 个研究点 分布在 1 个国家目标入组 166 人开始时间: 2013年12月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
166
试验地点
14
主要终点
To determine the true number of ALK positives and negatives of a qPCR assay for the detection in FFPE lung cancer biopsy specimens of ALK status in comparison with IHC and FISH ALK detection technologies.

研究概览

简要总结

The anaplastic lymphoma kinase gene(ALK) is mutated approximately 5% of non-small cell lung cancers. Testing for this gene is important because there are drugs known as ALK inhibitors that have been shown to significantly delay the progression of ALK-mutated lung cancers. There are a number of ways to test for the presence of the ALK gene in lung cancer biopsy tissue. One method involves making slides and staining them to detect the ALK protein. This is called immunohistochemistry. Another method called fluorescence in situ hybridization(FISH)is used to detect rearrangements of the ALK gene associated with lung cancer. Although both these tests are widely used to test for ALK gene abnormalities, the techniques may not always find the ALK gene mutation because they are not sensitive enough or not enough cancer cells are present in the lung biopsy.

This study is being performed to determine if a technique called quantitation polymerase chain reaction (qPCR) is as accurate or better at finding the ALK gene mutation in lung cancer biopsy tissue.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • You have a confirmed diagnosis of non-squamous, non-endocrine non-small cell lung cancer.
  • Your cancer biopsy has sufficient cancer cells to be tested for the (Epidermal Growth Factor Receptor (EGFR) mutation, the ALK fusion gene abnormality and the research ALK testing.
  • Your lung cancer biopsy is determined not to have a mutation in the EGFR gene.
  • You are 19 years old or older.
  • You fully understand the study and give informed consent to participate as demonstrated by signing the consent.

排除标准

  • 未提供

研究组 & 干预措施

IHC, FISH and qPCR ALK assays

Experimental

ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.

干预措施: ALK qPCR assay (Device)

结局指标

主要结局

To determine the true number of ALK positives and negatives of a qPCR assay for the detection in FFPE lung cancer biopsy specimens of ALK status in comparison with IHC and FISH ALK detection technologies.

时间窗: Up to 24 weeks after the completing of enrollment of 72 ALK negative and 72 ALK positive tumor blocks

次要结局

  • The analysis of plasma and serum collected from those patients with ALK-positive NSCLC to assess the feasibility for the use of non-invasive sampling in the diagnosis and disease monitoring of lung cancer.(After completion of enrollemnt of 72 ALK postive tumor blocks.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验